SCHEDULE 13G/A: Vivo Opportunity Funds Report 9.99% Stake in Unicycive Therapeutics

Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC, have reported a combined beneficial ownership of 9.99% of Unicycive Therapeutics, Inc.'s common stock as of March 31, 2025, including convertible preferred stock and warrants.

Summary

• Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity, LLC collectively beneficially own 60,961,729 shares of Unicycive Therapeutics, Inc. Common Stock.
• This ownership represents 9.99% of the Issuer's Common Stock outstanding as of May 14, 2025, which was reported as 120,629,281 shares in the Issuer's Quarterly Report on Form 10-Q.
• The total beneficial ownership includes 11,370,152 shares of existing Common Stock.
• It also includes 6,529,000 shares of Common Stock issuable upon conversion of Series A-2 Convertible Preferred Stock within 60 days.
• Additionally, 12,802,388 shares are issuable from Series A-3 Preferred Stock underlying Tranche A Warrants exercisable within 60 days.
• Another 11,638,534 shares are issuable from Series A-4 Preferred Stock underlying Tranche B Warrants exercisable within 60 days.
• Finally, 18,621,655 shares are issuable from Series A-5 Preferred Stock underlying Tranche C Warrants exercisable within 60 days.
• The Series A-2, A-3, A-4, and A-5 Preferred Stock contain provisions preventing conversion if it would result in the holder obtaining greater than 9.99% of the Issuer's voting securities, though the reported amounts reflect full potential conversion without giving effect to these blocking provisions.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing (Schedule 13G) reporting beneficial ownership and does not contain information that would typically influence sentiment positively or negatively regarding the issuer's operational or financial performance.

Future Outlook

NA

Industry Context

This document is a routine regulatory filing by an investor and does not provide specific insights into broader industry trends or competitive landscape for Unicycive Therapeutics, Inc.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure and the extent of a significant investor's stake in Unicycive Therapeutics, Inc.

Key Dates

Keywords

Unicycive Therapeutics, Vivo Opportunity Fund Holdings, Vivo Opportunity LLC, Schedule 13G, beneficial ownership, common stock, preferred stock, warrants, SEC filing